Avid Bioservices Inc (CDMO)

[entdoc]

Threes (and KT), as you know, I am not one to split hairs when it comes to survival statistics, but the conumdrum you are batting around about mean and median survival is intriguing. It is especially so when you consider the advanced cancer cohort is so variable in their proximity to death, as constrasted, for instance, with clinical trials for rheumatoid arthritics, or pain medication, or obesity. IMO early deaths would not be nearly so important as prolonged survival, yet waiting for the last few in the cohort to die before calculating mean survival does not seem practical either. Interesting. I'm sure someone has a reasonable and logical explanation for how this is dealt with. After all, the FDA is a part of the government. (!?!)